Literature DB >> 12270169

Albumin affinity tags increase peptide half-life in vivo.

Michael F T Koehler1, Kerry Zobel, Maureen H Beresini, Lisa D Caris, Daniel Combs, Brian D Paasch, Robert A Lazarus.   

Abstract

Small organic molecules that bind tightly to serum albumin were applied to the amino terminus of an anticoagulant peptide in an effort to increase its protein binding in vivo. The tagged peptides were evaluated for their ability to be retained on liquid chromatographic columns with serum albumins incorporated into the stationary phase. Those which demonstrated significant affinity were administered intravenously to rabbits and found to have significantly increased plasma half-lives. Novel affinity tags were identified by appending a focused library of compounds to a model tetrapeptide and evaluating the resulting compounds' ability to bind to the serum albumin columns. The most promising were synthesized as the full length peptides and again evaluated in vivo. They were found to have still longer half-lives than the first generation compounds.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12270169     DOI: 10.1016/s0960-894x(02)00610-8

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  14 in total

Review 1.  Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics.

Authors:  Alessandro Zorzi; Sara Linciano; Alessandro Angelini
Journal:  Medchemcomm       Date:  2019-06-06       Impact factor: 3.597

2.  Captides: rigid junctions between beta sheets and small molecules.

Authors:  Brandon L Kier; Niels H Andersen
Journal:  J Pept Sci       Date:  2014-06-06       Impact factor: 1.905

Review 3.  Derivatization with fatty acids in peptide and protein drug discovery.

Authors:  Peter Kurtzhals; Søren Østergaard; Erica Nishimura; Thomas Kjeldsen
Journal:  Nat Rev Drug Discov       Date:  2022-08-24       Impact factor: 112.288

4.  "Human and Mouse Cross-Reactive" Albumin-Binding Helix-Loop-Helix Peptide Tag for Prolonged Bioactivity of Therapeutic Proteins.

Authors:  Yuto Nakatani; Zhengmao Ye; Yuki Ishizue; Taishi Higashi; Teruko Imai; Ikuo Fujii; Masataka Michigami
Journal:  Mol Pharm       Date:  2022-05-28       Impact factor: 5.364

5.  Conjugation to albumin-binding molecule tags as a strategy to improve both efficacy and pharmacokinetic properties of the complement inhibitor compstatin.

Authors:  Yijun Huang; Edimara S Reis; Patrick J Knerr; Wilfred A van der Donk; Daniel Ricklin; John D Lambris
Journal:  ChemMedChem       Date:  2014-07-23       Impact factor: 3.466

Review 6.  Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy.

Authors:  Zhibo Liu; Xiaoyuan Chen
Journal:  Chem Soc Rev       Date:  2016-03-07       Impact factor: 54.564

7.  Identification of HN-1-Peptide Target in Head and Neck Squamous Cell Carcinoma Cells.

Authors:  Jozsef Dudas; Christin Idler; Georg Sprinzl; Andreas Bernkop-Schnuerch; Herbert Riechelmann
Journal:  ISRN Oncol       Date:  2011-05-03

Review 8.  Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics.

Authors:  Kine Marita Knudsen Sand; Malin Bern; Jeannette Nilsen; Hanna Theodora Noordzij; Inger Sandlie; Jan Terje Andersen
Journal:  Front Immunol       Date:  2015-01-26       Impact factor: 7.561

9.  Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides.

Authors:  Alessandro Zorzi; Simon J Middendorp; Jonas Wilbs; Kaycie Deyle; Christian Heinis
Journal:  Nat Commun       Date:  2017-07-17       Impact factor: 14.919

10.  Resolving Binding Events on the Multifunctional Human Serum Albumin.

Authors:  Lea Wenskowsky; Michael Wagner; Johannes Reusch; Herman Schreuder; Hans Matter; Till Opatz; Stefan Matthias Petry
Journal:  ChemMedChem       Date:  2020-03-19       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.